KRAS and familial pancreatic carcinoma: KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling make pancreatic cancer cells sensitive to albumin-conjugated drugs, such that the drugs are more likely to accumulate in cancer cells (Liu et al., 2019).